Read\u00a0the interview here<\/a>.<\/p>\n“It is a great honor to receive World Biz Magazine’s ‘Top 100 Innovation CEO’ Award. Developing novel therapeutics to patients with unmet needs is at the heart of Enzychem’s mission and culture. We will continue to innovate and advance the development of our therapies for the patients,” said Ki Young Sohn, Chairman and CEO of Enzychem Lifesciences.<\/p>\n
World\u00a0Biz\u00a0Magazine’s\u00a0Top\u00a0100\u00a0Innovation\u00a0CEO\u00a0Awards\u00a0celebrates\u00a0business\u00a0leaders\u00a0across the globe that are making major\u00a0strides\u00a0in\u00a0 their\u00a0industries.\u00a0It\u00a0recognizes\u00a0product, service,\u00a0functional, strategic, and managerial innovation. It also recognizes individuals showing exceptional commercial insight and market integrity. Sustainability forms a key cornerstone of the awards and is an integral part of the selection criteria. Every year over 40,000 leaders are shortlisted and following a stringent evaluation process, only 100 winners are selected.<\/p>\n
Mike Walters, Editor in Chief of World Biz Magazine: “We are pleased to announce Ki\u00a0Young Sohn as a recipient of the\u00a0Award. To be highlighted within the\u00a0Top 30 of the 100 winners is a testament to the pivotal role of Enzychem Lifesciences under Ki Young Sohn’s leadership in focusing on patients with significant unmet needs in oncology, inflammatory, and severe respiratory\u00a0diseases.\u00a0 Aside\u00a0from\u00a0its\u00a0innovation\u00a0DNA\u00a0and\u00a0exciting growth, Enzychem Lifesciences is an ESG centric company, best exemplified by its commitment to making COVID-19 vaccination available in low-medium income countries across Latin\u00a0America and\u00a0Asia.”<\/p>\n
World\u00a0Biz\u00a0Magazine\u00a0is\u00a0the\u00a0leading global\u00a0C-Suite\u00a0business journal\u00a0with\u00a0a\u00a0readership\u00a0spanning 32 countries, WBM focuses on leadership, innovation, investment and social responsibility. worldbizmagazine.net<\/a><\/p>\nEnzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic and inflammatory diseases. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis. Enzychem is headquartered in South Korea, with an office in the United States. enzychem.com<\/a><\/p>\nPress contact: John West, awards@worldbizmagazine.com<\/a><\/p>\nRelated Images<\/b><\/strong><\/p>\n <\/a><\/p>\nImage 1: KI YOUNG SOHN, CEO OF ENZYCHEM<\/b><\/strong> <\/a><\/p>\nThis content was issued through the press release distribution service at Newswire.com<\/a>.<\/p>\n